Comparing Drug Effects in Regulatory Animals and Humans with 3D in vitro Models
This pre-competitive consortium, organized and led by InSphero, aims to bring together representatives from pharmaceutical companies engaged and invested in the development of cross-species drug testing and validation strategies for rapid, reliable drug-induced liver injury (DILI) screening and prediction. Together, we will evaluate methods for recapitulating DILI-specific in vivo effects observed in animal models and patients using in vitro human and animal liver spheroid models and a comprehensive DILI compound library. Results will be submitted for publication in a high-profile scientific journal and for consideration as a special interest group topic at an upcoming Society of Toxicology annual meeting. For more information on the Consortium, download our PDF for full details of this exclusive program.
We seek for the characterization of 3D liver microtissue as decision-enabling drug development tool for first in human studies. We will identify models and methodologies that bridge the gap between human and animal in vivo and in vitro responses to a wide range of compounds and therapeutics.
Key Benefits for Consortium Members
Translational Safety Requirements
The proposal meets translational safety requirements with flexible adaptation to various drug safety questions.
Mutual Learning Opportunity
The consortium provides an innovative platform for the advancement of new drug development tools.
Cooperative publications and presentations at conferences will strengthen the regulatory impact providing high international visibility.
Proven Commitment to the 3R`s
Proven Commitment to the 3R`s. Replace animal studies with other methods. Reduce—As many trials as required, as few as possible. Refine—minimize stress of study animals.